Grupo Fisiopatoloxía Endócrina, Nutricional e Médica (FENM): Envíos recentes
Mostrando ítems 36-40 de 112
-
Clinical features and natural history of clinically non-functioning pituitary incidentalomas
(Bioscientifica, 2017) -
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: the ACROCOMB study
(Elsevier, 2016-11-04)[Abstract] PURPOSE: To describe real-world use of lanreotide combination therapy for acromegaly. PATIENTS AND METHODS: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated ... -
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program
(Taylor & Francis, 2014-07-07)[Abstract] BACKGROUND: Based on the TROPIC study results, cabazitaxel was approved for the management of metastatic castration-resistant prostate cancer (mCRPC) progressing on or after docetaxel. METHODS: This multi-centre ... -
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
(American Association for Cancer Research, 2014-02-17)[Abstract] PURPOSE: Figitumumab is a human IgG2 monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R), with antitumor activity in prostate cancer. This phase II trial randomized chemotherapy-naïve ... -
Maternal and perinatal outcomes after bariatric surgery: a spanish multicenter study
(Springer, 2014-08-15)[Abstract] Background. Bariatric surgery (BS) has become more frequent among women of child-bearing age. Data regarding the underlying maternal and perinatal risks are scarce. The objective of this nationwide study is to ...